share_log

创业慧康(300451.SZ)：与飞利浦合作的“新一代EMR软件产品”CTasy1.0核心系统本地化开发已经接近尾声

Venture Wellcome (300451.SZ): The localization development of the CTAsy1.0 core system, a “next-generation EMR software product” in collaboration with Philips, is nearing completion

Gelonghui Finance ·  Jan 11 04:29

Gelonghui, January 11丨An investor asked Venture Huikang (300451.SZ) on the investor interactive platform, “When will the cooperation between the company and Philips produce results?” The company replied that the localization development of the CTAsy1.0 core system, a “next-generation EMR software product” in cooperation with Philips, is nearing completion, and pilot projects are already underway. At present, CTAsy1.0 has basically completed the established R&D goals, and will be officially released later. According to the cooperation agreement between the two parties, after CTAsy1.0 is officially released, the cooperation between the two parties will enter the marketing and sales stage. Philips will act as the exclusive distributor of CTAsy1.0 to achieve the corresponding CTAsy1.0 sales target within its customer range according to the goals set by the two parties each year. Furthermore, in addition to traditional medical software sales, the strategic cooperation between the company and Philips will extend the scope of cooperation to sales and agents of various medical devices, and collaborate deeply on the channel and product side to achieve incremental customer and channel sharing, promote collaborative sales of the company's medical information technology products and Philips medical equipment, and bring new development impetus to the company's business development. Relevant cooperation is still in progress, and there are uncertainties such as policy, R&D, and market changes. Please pay attention to investment risks. For more company news, please pay attention to the company's official website and public account.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment